CEO Greg Behar contends the company is investing in the technologies, capabilities, and expertise needed to remain one of the industry’s leading CDMOs.
The capital project will add 160,000 liters of manufacturing capacity, increasing the total capacity by approximately 25% to nearly one million liters.
In this sponsored episode of Off Script, an industry expert at Valsynthese discusses the importance of flow chemistry in complex pharmaceutical manufacturing.
